The DOI matches its Crossref record; 560 of the 560 references it cites were found in a registry or an index.
Antibody Structure and Function: The Basis for Engineering Therapeutics
Open accessAbstract
Antibodies and antibody-derived macromolecules have established themselves as the mainstay in protein-based therapeutic molecules (biologics). Our knowledge of the structure–function relationships of antibodies provides a platform for protein engineering that has been exploited to generate a wide range of biologics for a host of therapeutic indications. In this review, our basic understanding of the antibody structure is described along with how that knowledge has leveraged the engineering of antibody and antibody-related therapeutics having the appropriate antigen affinity, effector function, and biophysical properties. The platforms examined include the development of antibodies, antibody fragments, bispecific antibody, and antibody fusion products, whose efficacy and manufacturability can be improved via humanization, affinity modulation, and stability enhancement. We also review the design and selection of binding arms, and avidity modulation. Different strategies of preparing bispecific and multispecific molecules for an array of therapeutic applications are included.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Berman, H. M. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.1.235 · Cited by 40,196
Signal transduction by receptors with tyrosine kinase activity
Ullrich, A., & Schlessinger, J. (1990) · Cell · doi:10.1016/0092-8674(90)90801-k · Cited by 5,435
Cancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893
Trastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834
Molecular mechanisms of T cell co-stimulation and co-inhibition
Chen, L., & Flies, D. B. (2013) · Nature Reviews Immunology · doi:10.1038/nri3405 · Cited by 3,114
FcRn: the neonatal Fc receptor comes of age
Roopenian, D. C., & Akilesh, S. (2007) · Nature Reviews Immunology · doi:10.1038/nri2155 · Cited by 2,346
The hydrolysis of rabbit γ-globulin and antibodies with crystalline papain
Porter, R. R. (1959) · Biochemical Journal · doi:10.1042/bj0730119 · Cited by 2,308
Nanobodies: natural single-domain antibodies
Muyldermans, S. (2013) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-063011-092449 · Cited by 2,304
The atomic structure of protein-protein recognition sites 1 1Edited by A. R. Fersht
Conte, L. L., Chothia, C., & Janin, J. (1999) · Journal of Molecular Biology · doi:10.1006/jmbi.1998.2439 · Cited by 1,964
Humanization of an anti-p185HER2 antibody for human cancer therapy.
Carter, P., Presta, L., Gorman, C. M., Ridgway, J. B., Henner, D., Wong, W. L., Rowland, A. M., Kotts, C., Carver, M. E., & Shepard, H. M. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.10.4285 · Cited by 1,918
Shields, R. L., Lai, J., Keck, R., O'Connell, L. Y., Hong, K., Meng, Y. G., Weikert, S. H. A., & Presta, L. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202069200 · Cited by 1,835
Structure of a nanobody-stabilized active state of the β2 adrenoceptor
Rasmussen, S. G. F., Choi, H.-J., Fung, J. J., Pardon, E., Casarosa, P., Chae, P. S., DeVree, B. T., Rosenbaum, D. M., Thian, F. S., Kobilka, T. S., et al. (2011) · Nature · doi:10.1038/nature09648 · Cited by 1,680
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate
Lewis Phillips, G. D., Li, G., Dugger, D. L., Crocker, L. M., Parsons, K. L., Mai, E., Blättler, W. A., Lambert, J. M., Chari, R. V. J., Lutz, R. J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1776 · Cited by 1,676
Reshaping human antibodies for therapy
Riechmann, L., Clark, M., Waldmann, H., & Winter, G. (1988) · Nature · doi:10.1038/332323a0 · Cited by 1,562
Deisenhofer, J. (1981) · PubMed · Cited by 1,422
Shinkawa, T., Nakamura, K., Yamane, N., Shoji-Hosaka, E., Kanda, Y., Sakurada, M., Uchida, K., Anazawa, H., Satoh, M., Yamasaki, M., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210665200 · Cited by 1,413
Replacing the complementarity-determining regions in a human antibody with those from a mouse
Jones, P. T., Dear, P. H., Foote, J., Neuberger, M. S., & Winter, G. (1986) · Nature · doi:10.1038/321522a0 · Cited by 1,406
Canonical structures for the hypervariable regions of immunoglobulins
Chothia, C., & Lesk, A. M. (1987) · Journal of Molecular Biology · doi:10.1016/0022-2836(87)90412-8 · Cited by 1,406
Therapeutic antibodies: successes, limitations and hopes for the future
Chames, P., Van Regenmortel, M., Weiss, E., & Baty, D. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00190.x · Cited by 1,382
Wu, T. T., & Kabat, E. A. (1970) · The Journal of Experimental Medicine · doi:10.1084/jem.132.2.211 · Cited by 1,340
Deisenhofer, J. (1981) · Biochemistry · doi:10.1021/bi00512a001 · Cited by 1,333
Antibody Recognition of a Highly Conserved Influenza Virus Epitope
Ekiert, D. C., Bhabha, G., Elsliger, M.-A., Friesen, R. H. E., Jongeneelen, M., Throsby, M., Goudsmit, J., & Wilson, I. A. (2009) · Science · doi:10.1126/science.1171491 · Cited by 1,326
Geiger, T., & Clarke, S. (1987) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)75855-4 · Cited by 1,311
Bispecific antibodies: a mechanistic review of the pipeline
Labrijn, A. F., Janmaat, M. L., Reichert, J. M., & Parren, P. W. H. I. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0028-1 · Cited by 1,303
Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate
Hamblett, K. J., Senter, P. D., Chace, D. F., Sun, M. M. C., Lenox, J., Cerveny, C. G., Kissler, K. M., Bernhardt, S. X., Kopcha, A. K., Zabinski, R. F., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0789 · Cited by 1,247
Daëron, M. (1997) · Annual Review of Immunology · doi:10.1146/annurev.immunol.15.1.203 · Cited by 1,227
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
Doronina, S. O., Toki, B. E., Torgov, M. Y., Mendelsohn, B. A., Cerveny, C. G., Chace, D. F., DeBlanc, R. L., Gearing, R. P., Bovee, T. D., Siegall, C. B., et al. (2003) · Nature Biotechnology · doi:10.1038/nbt832 · Cited by 1,206
Conformations of immunoglobulin hypervariable regions
Chothia, C., Lesk, A. M., Tramontano, A., Levitt, M., Smith-Gill, S. J., Air, G., Sheriff, S., Padlan, E. A., Davies, D., Tulip, W. R., et al. (1989) · Nature · doi:10.1038/342877a0 · Cited by 1,185
Shields, R. L., Namenuk, A. K., Hong, K., Meng, Y. G., Rae, J., Briggs, J., Xie, D., Lai, J., Stadlen, A., Li, B., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009483200 · Cited by 1,161
A MODIFICATION OF RECEPTOR THEORY
STEPHENSON, R. P. (1956) · British Journal of Pharmacology and Chemotherapy · doi:10.1111/j.1476-5381.1956.tb00006.x · Cited by 1,156
IMGT(R), the international ImMunoGeneTics information system(R)
Lefranc, M.-P., Giudicelli, V., Ginestoux, C., Jabado-Michaloud, J., Folch, G., Bellahcene, F., Wu, Y., Gemrot, E., Brochet, X., Lane, J., et al. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn838 · Cited by 1,119
Coadministration of a Tumor-Penetrating Peptide Enhances the Efficacy of Cancer Drugs
Sugahara, K. N., Teesalu, T., Karmali, P. P., Kotamraju, V. R., Agemy, L., Greenwald, D. R., & Ruoslahti, E. (2010) · Science · doi:10.1126/science.1183057 · Cited by 1,075
Structure-Function of the G Protein–Coupled Receptor Superfamily
Katritch, V., Cherezov, V., & Stevens, R. C. (2013) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-032112-135923 · Cited by 1,054
Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains.
Morrison, S. L., Johnson, M. J., Herzenberg, L. A., & Oi, V. T. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.21.6851 · Cited by 1,039
Anti-Inflammatory Activity of Human IgG4 Antibodies by Dynamic Fab Arm Exchange
van der Neut Kolfschoten, M., Schuurman, J., Losen, M., Bleeker, W. K., Martínez-Martínez, P., Vermeulen, E., den Bleker, T. H., Wiegman, L., Vink, T., Aarden, L. A., et al. (2007) · Science · doi:10.1126/science.1144603 · Cited by 975
The making of bispecific antibodies
Brinkmann, U., & Kontermann, R. E. (2017) · mAbs · doi:10.1080/19420862.2016.1268307 · Cited by 923
"Diabodies": small bivalent and bispecific antibody fragments.
Holliger, P., Prospero, T., & Winter, G. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.14.6444 · Cited by 874
Highly Conserved Protective Epitopes on Influenza B Viruses
Dreyfus, C., Laursen, N. S., Kwaks, T., Zuijdgeest, D., Khayat, R., Ekiert, D. C., Lee, J. H., Metlagel, Z., Bujny, M. V., Jongeneelen, M., et al. (2012) · Science · doi:10.1126/science.1222908 · Cited by 866
Properties of mouse and human IgG receptors and their contribution to disease models
Bruhns, P. (2012) · Blood · doi:10.1182/blood-2012-01-380121 · Cited by 847
Glycosylation as a strategy to improve antibody-based therapeutics
Jefferis, R. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2804 · Cited by 829 · cited 1×
“Likewise, glycosylation patterns can impact both PK and PD significantly [259,260].”
Background‘Knobs-into-holes’ engineering of antibody CH3 domains for heavy chain heterodimerization
Ridgway, J. B. B., Presta, L. G., & Carter, P. (1996) · "Protein Engineering, Design and Selection" · doi:10.1093/protein/9.7.617 · Cited by 810
Engineered antibody Fc variants with enhanced effector function
Lazar, G. A., Dang, W., Karki, S., Vafa, O., Peng, J. S., Hyun, L., Chan, C., Chung, H. S., Eivazi, A., Yoder, S. C., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508123103 · Cited by 803
Complement Is Activated by IgG Hexamers Assembled at the Cell Surface
Diebolder, C. A., Beurskens, F. J., de Jong, R. N., Koning, R. I., Strumane, K., Lindorfer, M. A., Voorhorst, M., Ugurlar, D., Rosati, S., Heck, A. J. R., et al. (2014) · Science · doi:10.1126/science.1248943 · Cited by 796
DiLillo, D. J., Tan, G. S., Palese, P., & Ravetch, J. V. (2014) · Nature Medicine · doi:10.1038/nm.3443 · Cited by 749
Harding, F. A., Stickler, M. M., Razo, J., & DuBridge, R. (2010) · mAbs · doi:10.4161/mabs.2.3.11641 · Cited by 737
Antibody Multispecificity Mediated by Conformational Diversity
James, L. C., Roversi, P., & Tawfik, D. S. (2003) · Science · doi:10.1126/science.1079731 · Cited by 719
Standard conformations for the canonical structures of immunoglobulins 1 1Edited by I. A. Wilson
Al-Lazikani, B., Lesk, A. M., & Chothia, C. (1997) · Journal of Molecular Biology · doi:10.1006/jmbi.1997.1354 · Cited by 706
Three-Dimensional Structure of Immunoglobulins
Amzel, L. M., & Poljak, R. J. (1979) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.48.070179.004525 · Cited by 692
Junghans, R. P., & Anderson, C. L. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.11.5512 · Cited by 684
Krapp, S., Mimura, Y., Jefferis, R., Huber, R., & Sondermann, P. (2003) · Journal of Molecular Biology · doi:10.1016/s0022-2836(02)01250-0 · Cited by 674
Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura
Peyvandi, F., Scully, M., Kremer Hovinga, J. A., Cataland, S., Knöbl, P., Wu, H., Artoni, A., Westwood, J.-P., Mansouri Taleghani, M., Jilma, B., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1505533 · Cited by 666
Enhanced antibody half-life improves in vivo activity
Zalevsky, J., Chamberlain, A. K., Horton, H. M., Karki, S., Leung, I. W. L., Sproule, T. J., Lazar, G. A., Roopenian, D. C., & Desjarlais, J. R. (2010) · Nature Biotechnology · doi:10.1038/nbt.1601 · Cited by 653
Properties of Human IgG1s Engineered for Enhanced Binding to the Neonatal Fc Receptor (FcRn)
Dall'Acqua, W. F., Kiener, P. A., & Wu, H. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m604292200 · Cited by 646
The function of Fcγ receptors in dendritic cells and macrophages
Guilliams, M., Bruhns, P., Saeys, Y., Hammad, H., & Lambrecht, B. N. (2014) · Nature Reviews Immunology · doi:10.1038/nri3582 · Cited by 639
Mutation Drift and Repertoire Shift in the Maturation of the Immune Response
Berek, C., & Milstein, C. (1987) · Immunological Reviews · doi:10.1111/j.1600-065x.1987.tb00507.x · Cited by 632
Immunogenicity of engineered antibodies
Hwang, W. Y. K., & Foote, J. (2005) · Methods · doi:10.1016/j.ymeth.2005.01.001 · Cited by 630
Biophysical properties of the clinical-stage antibody landscape
Jain, T., Sun, T., Durand, S., Hall, A., Houston, N. R., Nett, J. H., Sharkey, B., Bobrowicz, B., Caffry, I., Yu, Y., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1616408114 · Cited by 629 · cited 2×
“When applied to the experimentally characterized antibodies in the clinical stage [277], AggScore accurately identified aggregation-prone regions and predicted changes in aggregation behavior upon residue mutation.”
BackgroundMethodA humanized antibody that binds to the interleukin 2 receptor.
Queen, C., Schneider, W. P., Selick, H. E., Payne, P. W., Landolfi, N. F., Duncan, J. F., Avdalovic, N. M., Levitt, M., Junghans, R. P., & Waldmann, T. A. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.24.10029 · Cited by 627
Antibody tumor penetration: Transport opposed by systemic and antigen-mediated clearance
Thurber, G. M., Schmidt, M. M., & Wittrup, K. D. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.04.012 · Cited by 624
Stability engineering of antibody single-chain Fv fragments
Wörn, A., & Plückthun, A. (2001) · Journal of Molecular Biology · doi:10.1006/jmbi.2000.4265 · Cited by 616
The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD20
Teeling, J. L., Mackus, W. J. M., Wiegman, L. J. J. M., van den Brakel, J. H. N., Beers, S. A., French, R. R., van Meerten, T., Ebeling, S., Vink, T., Slootstra, J. W., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.1.362 · Cited by 609
Alternative molecular formats and therapeutic applications for bispecific antibodies
Spiess, C., Zhai, Q., & Carter, P. J. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.01.003 · Cited by 607
Nanobodies and nanobody-based human heavy chain antibodies as antitumor therapeutics
Bannas, P., Hambach, J., & Koch-Nolte, F. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01603 · Cited by 572 · cited 1×
“hydrophobic interfaces that allow for chain pairing, VHH and VNAR domains are naturally monomeric and tend to have more hydrophilic surfaces [511].”
BackgroundInteractions of protein antigens with antibodies.
Davies, D. R., & Cohen, G. H. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.1.7 · Cited by 550
Radioimmunotherapy of B-Cell Lymphoma with [131I]Anti-B1 (Anti-CD20) Antibody
Kaminski, M. S., Zasadny, K. R., Francis, I. R., Milik, A. W., Ross, C. W., Moon, S. D., Crawford, S. M., Burgess, J. M., Petry, N. A., Butchko, G. M., et al. (1993) · New England Journal of Medicine · doi:10.1056/nejm199308123290703 · Cited by 547
Ox-40 Ligand: A Potent Costimulatory Molecule for Sustaining Primary CD4 T Cell Responses
Gramaglia, I., Weinberg, A. D., Lemon, M., & Croft, M. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.12.6510 · Cited by 527
Glycosylation of Recombinant Antibody Therapeutics
Jefferis, R. (2008) · Biotechnology Progress · doi:10.1021/bp040016j · Cited by 526
Antibody framework residues affecting the conformation of the hypervariable loops
Foote, J., & Winter, G. (1992) · Journal of Molecular Biology · doi:10.1016/0022-2836(92)91010-m · Cited by 524
Antibody-antigen interactions: new structures and new conformational changes
Wilson, I. A., & Stanfield, R. L. (1994) · Current Opinion in Structural Biology · doi:10.1016/0959-440x(94)90267-4 · Cited by 515
Doronina, S. O., Mendelsohn, B. A., Bovee, T. D., Cerveny, C. G., Alley, S. C., Meyer, D. L., Oflazoglu, E., Toki, B. E., Sanderson, R. J., Zabinski, R. F., et al. (2006) · Bioconjugate Chemistry · doi:10.1021/bc0502917 · Cited by 515
Sievers, E. L., Appelbaum, F. R., Spielberger, R. T., Forman, S. J., Flowers, D., Smith, F. O., Shannon-Dorcy, K., Berger, M. S., & Bernstein, I. D. (1999) · Blood · doi:10.1182/blood.v93.11.3678 · Cited by 512
Stephenson, R. C., & Clarke, S. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)83327-0 · Cited by 511
An efficient route to human bispecific IgG
Merchant, A. M., Zhu, Z., Yuan, J. Q., Goddard, A., Adams, C. W., Presta, L. G., & Carter, P. (1998) · Nature Biotechnology · doi:10.1038/nbt0798-677 · Cited by 510
Kitazawa, T., Igawa, T., Sampei, Z., Muto, A., Kojima, T., Soeda, T., Yoshihashi, K., Okuyama-Nishida, Y., Saito, H., Tsunoda, H., et al. (2012) · Nature Medicine · doi:10.1038/nm.2942 · Cited by 507
The TNF Family of Ligands and Receptors: Communication Modules in the Immune System and Beyond
Dostert, C., Grusdat, M., Letellier, E., & Brenner, D. (2019) · Physiological Reviews · doi:10.1152/physrev.00045.2017 · Cited by 498
Batista, F. D., & Neuberger, M. S. (1998) · Immunity · doi:10.1016/s1074-7613(00)80580-4 · Cited by 481
Creed, D. (1984) · Photochemistry and Photobiology · doi:10.1111/j.1751-1097.1984.tb03890.x · Cited by 477
Fc‐fusion proteins: new developments and future perspectives
Czajkowsky, D. M., Hu, J., Shao, Z., & Pleass, R. J. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201201379 · Cited by 476
Humanization of an antibody directed against IgE.
Presta, L. G., Lahr, S. J., Shields, R. L., Porter, J. P., Gorman, C. M., Fendly, B. M., & Jardieu, P. M. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.151.5.2623 · Cited by 474
Refined Structure of an Intact IgG2a Monoclonal Antibody,
Harris, L. J., Larson, S. B., Hasel, K. W., & McPherson, A. (1997) · Biochemistry · doi:10.1021/bi962514+ · Cited by 451
A Theoretical Model of γ-Globulin Catabolism
BRAMBELL, F. W. R., HEMMINGS, W. A., & MORRIS, I. G. (1964) · Nature · doi:10.1038/2031352a0 · Cited by 449
Bulliard, Y., Jolicoeur, R., Windman, M., Rue, S. M., Ettenberg, S., Knee, D. A., Wilson, N. S., Dranoff, G., & Brogdon, J. L. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130573 · Cited by 446
Löffler, A., Kufer, P., Lutterbüse, R., Zettl, F., Daniel, P. T., Schwenkenbecher, J. M., Riethmüller, G., Dörken, B., & Bargou, R. C. (2000) · Blood · doi:10.1182/blood.v95.6.2098 · Cited by 445
On the Nature of the Multivalency Effect: A Thermodynamic Model
Kitov, P. I., & Bundle, D. R. (2003) · Journal of the American Chemical Society · doi:10.1021/ja038223n · Cited by 445
Kaplon, H., & Reichert, J. M. (2019) · mAbs · doi:10.1080/19420862.2018.1556465 · Cited by 434
Crystal structure of the complex of rat neonatal Fc receptor with Fc
Burmeister, W. P., Huber, A. H., & Bjorkman, P. J. (1994) · Nature · doi:10.1038/372379a0 · Cited by 431
Liu, L. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24444 · Cited by 428
Goebeler, M.-E., Knop, S., Viardot, A., Kufer, P., Topp, M. S., Einsele, H., Noppeney, R., Hess, G., Kallert, S., Mackensen, A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.1586 · Cited by 428
Inducible T cell antigen 4-1BB. Analysis of expression and function
Pollok, K. E., Kim, Y. J., Zhou, Z., Hurtado, J., Kim, K. K., Pickard, R. T., & Kwon, B. S. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.150.3.771 · Cited by 421
Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels
Vaccaro, C., Zhou, J., Ober, R. J., & Ward, E. S. (2005) · Nature Biotechnology · doi:10.1038/nbt1143 · Cited by 407
Effects of Charge on Antibody Tissue Distribution and Pharmacokinetics
Boswell, C. A., Tesar, D. B., Mukhyala, K., Theil, F.-P., Fielder, P. J., & Khawli, L. A. (2010) · Bioconjugate Chemistry · doi:10.1021/bc100261d · Cited by 398
Structural repertoire of the human VH segments
Chothia, C., Lesk, A. M., Gherardi, E., Tomlinson, I. M., Walter, G., Marks, J. D., Llewelyn, M. B., & Winter, G. (1992) · Journal of Molecular Biology · doi:10.1016/0022-2836(92)90224-8 · Cited by 394
Klein, C., Lammens, A., Schäfer, W., Georges, G., Schwaiger, M., Mössner, E., Hopfner, K.-P., Umaña, P., & Niederfellner, G. (2013) · mAbs · doi:10.4161/mabs.22771 · Cited by 392
Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins
Liu, L. (2018) · Protein & Cell · doi:10.1007/s13238-017-0408-4 · Cited by 390
Three-Dimensional Structure of the Fab′ Fragment of a Human Immunoglobulin at 2.8-Å Resolution
Poljak, R. J., Amzel, L. M., Avey, H. P., Chen, B. L., Phizackerley, R. P., & Saul, F. (1973) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.70.12.3305 · Cited by 384
Crystal structure of the complex of rat neonatal Fc receptor with Fc
(1995) · Trends in Genetics · doi:10.1016/0168-9525(95)90005-5 · Cited by 381
A new clustering of antibody CDR loop conformations
North, B., Lehmann, A., & Dunbrack, R. L. (2011) · Journal of Molecular Biology · doi:10.1016/j.jmb.2010.10.030 · Cited by 380
Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates
Yu, Y. J., Atwal, J. K., Zhang, Y., Tong, R. K., Wildsmith, K. R., Tan, C., Bien-Ly, N., Hersom, M., Maloney, J. A., Meilandt, W. J., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009835 · Cited by 371
Variants of the Antibody Herceptin That Interact with HER2 and VEGF at the Antigen Binding Site
Bostrom, J., Yu, S.-F., Kan, D., Appleton, B. A., Lee, C. V., Billeci, K., Man, W., Peale, F., Ross, S., Wiesmann, C., et al. (2009) · Science · doi:10.1126/science.1165480 · Cited by 370
Structural Basis of Antibody Function
Davies, D. R., & Metzger, H. (1983) · Annual Review of Immunology · doi:10.1146/annurev.iy.01.040183.000511 · Cited by 369
Kinetic and affinity limits on antibodies produced during immune responses.
Foote, J., & Eisen, H. N. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.5.1254 · Cited by 368
Increasing the Affinity of a Human IgG1 for the Neonatal Fc Receptor: Biological Consequences
Acqua, W. F. D., Woods, R. M., Ward, E. S., Palaszynski, S. R., Patel, N. K., Brewah, Y. A., Wu, H., Kiener, P. A., & Langermann, S. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.9.5171 · Cited by 368
Robbie, G. J., Criste, R., Dall'Acqua, W. F., Jensen, K., Patel, N. K., Losonsky, G. A., & Griffin, M. P. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01285-13 · Cited by 366
Linkers in the structural biology of protein–protein interactions
Reddy Chichili, V. P., Kumar, V., & Sivaraman, J. (2013) · Protein Science · doi:10.1002/pro.2206 · Cited by 363
DiJoseph, J. F., Armellino, D. C., Boghaert, E. R., Khandke, K., Dougher, M. M., Sridharan, L., Kunz, A., Hamann, P. R., Gorovits, B., Udata, C., et al. (2004) · Blood · doi:10.1182/blood-2003-07-2466 · Cited by 361
IgG Fc engineering to modulate antibody effector functions
Wang, X., Mathieu, M., & Brezski, R. J. (2018) · Protein & Cell · doi:10.1007/s13238-017-0473-8 · Cited by 356
Selective oxidation of methionine residues in proteins
Shechter, Y., Burstein, Y., & Patchornik, A. (1975) · Biochemistry · doi:10.1021/bi00691a025 · Cited by 356
Structure of a λ-type Bence-Jones protein at 3.5-Å resolution
Schiffer, M., Girling, R. L., Ely, K. R., & Edmundson, A. B. (1973) · Biochemistry · doi:10.1021/bi00747a013 · Cited by 355
The Carbohydrate at FcγRIIIa Asn-162
Ferrara, C., Stuart, F., Sondermann, P., Brünker, P., & Umaña, P. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m510171200 · Cited by 354
Mack, M., Riethmüller, G., & Kufer, P. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.15.7021 · Cited by 351
Leach, J. L., Sedmak, D. D., Osborne, J. M., Rahill, B., Lairmore, M. D., & Anderson, C. L. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.157.8.3317 · Cited by 348
Liang, W.-C., Wu, X., Peale, F. V., Lee, C. V., Meng, Y. G., Gutierrez, J., Fu, L., Malik, A. K., Gerber, H.-P., Ferrara, N., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m508199200 · Cited by 346
Reshaping Human Antibodies: Grafting an Antilysozyme Activity
Verhoeyen, M., Milstein, C., & Winter, G. (1988) · Science · doi:10.1126/science.2451287 · Cited by 345
Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin
Wu, C., Ying, H., Grinnell, C., Bryant, S., Miller, R., Clabbers, A., Bose, S., McCarthy, D., Zhu, R.-R., Santora, L., et al. (2007) · Nature Biotechnology · doi:10.1038/nbt1345 · Cited by 344
Computational design of antibody-affinity improvement beyond in vivo maturation
Lippow, S. M., Wittrup, K. D., & Tidor, B. (2007) · Nature Biotechnology · doi:10.1038/nbt1336 · Cited by 342
Schaefer, G., Haber, L., Crocker, L. M., Shia, S., Shao, L., Dowbenko, D., Totpal, K., Wong, A., Lee, C. V., Stawicki, S., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.09.003 · Cited by 341
Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange
Labrijn, A. F., Meesters, J. I., de Goeij, B. E. C. G., van den Bremer, E. T. J., Neijssen, J., van Kampen, M. D., Strumane, K., Verploegen, S., Kundu, A., Gramer, M. J., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1220145110 · Cited by 339
Crystal structure at 2.2 Å resolution of the MHC-related neonatal Fc receptor
Burmeister, W. P., Gastinel, L. N., Simister, N. E., Blum, M. L., & Bjorkman, P. J. (1994) · Nature · doi:10.1038/372336a0 · Cited by 337
Sampei, Z., Igawa, T., Soeda, T., Okuyama-Nishida, Y., Moriyama, C., Wakabayashi, T., Tanaka, E., Muto, A., Kojima, T., Kitazawa, T., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057479 · Cited by 336
Yang, W.-P., Green, K., Pinz-Sweeney, S., Briones, A. T., Burton, D. R., & Barbas III, C. F. (1995) · Journal of Molecular Biology · doi:10.1006/jmbi.1995.0626 · Cited by 333
Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action
Jefferis, R. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.04.007 · Cited by 330
Nanobodies and Their Potential Applications
Hassanzadeh-Ghassabeh, G., Devoogdt, N., De Pauw, P., Vincke, C., & Muyldermans, S. (2013) · Nanomedicine · doi:10.2217/nnm.13.86 · Cited by 328
Morea, V., Tramontano, A., Rustici, M., Chothia, C., & Lesk, A. M. (1998) · Journal of Molecular Biology · doi:10.1006/jmbi.1997.1442 · Cited by 327
Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma.
Knox, S. J., Goris, M. L., Trisler, K. D., Negrin, R. S., Davis, T., Liles, T. M., Grillo-López, A. J., Chinn, P. C., Varns, C., Ning, S., et al. (1996) · PubMed · Cited by 326
Optimization of antibody binding to FcγRIIa enhances macrophage phagocytosis of tumor cells
Richards, J. O., Karki, S., Lazar, G. A., Chen, H., Dang, W., & Desjarlais, J. R. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0201 · Cited by 313
Ritchie, M., Tchistiakova, L., & Scott, N. (2013) · mAbs · doi:10.4161/mabs.22854 · Cited by 312
Principles, approaches, and challenges for predicting protein aggregation rates and shelf life
Weiss, W. F., Young, T. M., & Roberts, C. J. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21521 · Cited by 308
Ferrara, C., Brünker, P., Suter, T., Moser, S., Püntener, U., & Umaña, P. (2006) · Biotechnology and Bioengineering · doi:10.1002/bit.20777 · Cited by 305
Cardillo, T. M., Govindan, S. V., Sharkey, R. M., Trisal, P., Arrojo, R., Liu, D., Rossi, E. A., Chang, C.-H., & Goldenberg, D. M. (2015) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5b00223 · Cited by 304
Huhn, C., Selman, M. H. J., Ruhaak, L. R., Deelder, A. M., & Wuhrer, M. (2009) · PROTEOMICS · doi:10.1002/pmic.200800715 · Cited by 301
Els Conrath, K., Lauwereys, M., Wyns, L., & Muyldermans, S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m007734200 · Cited by 300
Somatic mutation hotspots correlate with DNA polymerase η error spectrum
Rogozin, I. B., Pavlov, Y. I., Bebenek, K., Matsuda, T., & Kunkel, T. A. (2001) · Nature Immunology · doi:10.1038/88732 · Cited by 298
Biochemistry and physiological role of methionine sulfoxide residues in proteins
Brot, N., & Weissbach, H. (1983) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(83)90592-1 · Cited by 296
Creed, D. (1984) · Photochemistry and Photobiology · doi:10.1111/j.1751-1097.1984.tb03891.x · Cited by 295
Bispecific antibodies: design, therapy, perspectives
Sedykh, S., Prinz, V., Buneva, V., & Nevinsky, G. (2018) · Drug Design, Development and Therapy · doi:10.2147/dddt.s151282 · Cited by 292
A review of bispecific antibodies and antibody constructs in oncology and clinical challenges
Suurs, F. V., Lub-de Hooge, M. N., de Vries, E. G. E., & de Groot, D. J. A. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.04.006 · Cited by 292
Engineered Antibodies with Increased Activity to Recruit Complement
Idusogie, E. E., Wong, P. Y., Presta, L. G., Gazzano-Santoro, H., Totpal, K., Ultsch, M., & Mulkerrin, M. G. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.4.2571 · Cited by 291
Xenaki, K. T., Oliveira, S., & van Bergen en Henegouwen, P. M. P. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01287 · Cited by 289
Lee, H. S., Qi, Y., & Im, W. (2015) · Scientific Reports · doi:10.1038/srep08926 · Cited by 288
Bispecific antibodies and their applications
Fan, G., Wang, Z., Hao, M., & Li, J. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0227-0 · Cited by 288
Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity
Maynard, J. A., Maassen, C. B. M., Leppla, S. H., Brasky, K., Patterson, J. L., Iverson, B. L., & Georgiou, G. (2002) · Nature Biotechnology · doi:10.1038/nbt0602-597 · Cited by 287
Moores, S. L., Chiu, M. L., Bushey, B. S., Chevalier, K., Luistro, L., Dorn, K., Brezski, R. J., Haytko, P., Kelly, T., Wu, S.-J., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2833 · Cited by 286
Self-citationKanamaru, F., Youngnak, P., Hashiguchi, M., Nishioka, T., Takahashi, T., Sakaguchi, S., Ishikawa, I., & Azuma, M. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.12.7306 · Cited by 285
OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy
Bulliard, Y., Jolicoeur, R., Zhang, J., Dranoff, G., Wilson, N. S., & Brogdon, J. L. (2014) · Immunology & Cell Biology · doi:10.1038/icb.2014.26 · Cited by 284
Stavenhagen, J. B., Gorlatov, S., Tuaillon, N., Rankin, C. T., Li, H., Burke, S., Huang, L., Johnson, S., Bonvini, E., & Koenig, S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0696 · Cited by 284
Enzyme‐MOF Nanoreactor Activates Nontoxic Paracetamol for Cancer Therapy
Lian, X., Huang, Y., Zhu, Y., Fang, Y., Zhao, R., Joseph, E., Li, J., Pellois, J., & Zhou, H. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201801378 · Cited by 283
An Engineered Human IgG1 Antibody with Longer Serum Half-Life
Hinton, P. R., Xiong, J. M., Johlfs, M. G., Tang, M. T., Keller, S., & Tsurushita, N. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.1.346 · Cited by 282
Tumor-Specific Activation of an EGFR-Targeting Probody Enhances Therapeutic Index
Desnoyers, L. R., Vasiljeva, O., Richardson, J. H., Yang, A., Menendez, E. E. M., Liang, T. W., Wong, C., Bessette, P. H., Kamath, K., Moore, S. J., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006682 · Cited by 281
Enhancing Antibody Fc Heterodimer Formation through Electrostatic Steering Effects
Gunasekaran, K., Pentony, M., Shen, M., Garrett, L., Forte, C., Woodward, A., Ng, S. B., Born, T., Retter, M., Manchulenko, K., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.117382 · Cited by 280
Structural principles of tumor necrosis factor superfamily signaling
Vanamee, É. S., & Faustman, D. L. (2018) · Science Signaling · doi:10.1126/scisignal.aao4910 · Cited by 280
The mechanism of intestinal uptake and transcellular transport of IgG in the neonatal rat
Jones, E. A., & Waldmann, T. A. (1972) · Journal of Clinical Investigation · doi:10.1172/jci107116 · Cited by 279
Current progress in innovative engineered antibodies
Strohl, W. R. (2018) · Protein & Cell · doi:10.1007/s13238-017-0457-8 · Cited by 279
Design and Production of Bispecific Antibodies
Wang, Q., Chen, Y., Park, J., Liu, X., Hu, Y., Wang, T., McFarland, K., & Betenbaugh, M. J. (2019) · Antibodies · doi:10.3390/antib8030043 · Cited by 279
Structural Comparison of Fucosylated and Nonfucosylated Fc Fragments of Human Immunoglobulin G1
Matsumiya, S., Yamaguchi, Y., Saito, J.-I., Nagano, M., Sasakawa, H., Otaki, S., Satoh, M., Shitara, K., & Kato, K. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.02.034 · Cited by 278
A Therapeutic Antibody Targeting BACE1 Inhibits Amyloid-β Production in Vivo
Atwal, J. K., Chen, Y., Chiu, C., Mortensen, D. L., Meilandt, W. J., Liu, Y., Heise, C. E., Hoyte, K., Luk, W., Lu, Y., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002254 · Cited by 274
Lenting, P. J., Denis, C. V., & Christophe, O. D. (2017) · Blood · doi:10.1182/blood-2017-08-801662 · Cited by 269
Addressing Safety Liabilities of TfR Bispecific Antibodies That Cross the Blood-Brain Barrier
Couch, J. A., Yu, Y. J., Zhang, Y., Tarrant, J. M., Fuji, R. N., Meilandt, W. J., Solanoy, H., Tong, R. K., Hoyte, K., Luk, W., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005338 · Cited by 268
Immunoconjugates containing novel maytansinoids: promising anticancer drugs.
CHARI, R. V. J., Martell, B., Gross, J. L., Cook, S., Shah, S. A., Blättler, W. A., McKenzie, S. J., & Goldmacher, V. S. (1992) · PubMed · Cited by 266
Moore, G. L., Chen, H., Karki, S., & Lazar, G. A. (2010) · mAbs · doi:10.4161/mabs.2.2.11158 · Cited by 266
Reduced elimination of IgG antibodies by engineering the variable region
Igawa, T., Tsunoda, H., Tachibana, T., Maeda, A., Mimoto, F., Moriyama, C., Nanami, M., Sekimori, Y., Nabuchi, Y., Aso, Y., et al. (2010) · Protein Engineering Design and Selection · doi:10.1093/protein/gzq009 · Cited by 265 · cited 1×
“Consistent with this explanation, engineering IgG variable regions to remove patches of positive charge (without greatly altering protein pI) has also been used to reduce non-specific binding and improve PK [455].”
IMGT, the international ImMunoGeneTics information system(R)
Lefranc, M.-P. (2004) · Nucleic Acids Research · doi:10.1093/nar/gki065 · Cited by 265
Conformational isomerism and the diversity of antibodies.
Foote, J., & Milstein, C. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.22.10370 · Cited by 263
Atwell, S., Ridgway, J. B. B., Wells, J. A., & Carter, P. (1997) · Journal of Molecular Biology · doi:10.1006/jmbi.1997.1116 · Cited by 261
Heterogeneity of Monoclonal Antibodies Revealed by Charge-Sensitive Methods
Vlasak, J., & Ionescu, R. (2008) · Current Pharmaceutical Biotechnology · doi:10.2174/138920108786786402 · Cited by 260
Structural Insights into Neonatal Fc Receptor-based Recycling Mechanisms
Oganesyan, V., Damschroder, M. M., Cook, K. E., Li, Q., Gao, C., Wu, H., & Dall'Acqua, W. F. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.537563 · Cited by 259
Impact of methionine oxidation in human IgG1 Fc on serum half-life of monoclonal antibodies
Wang, W., Vlasak, J., Li, Y., Pristatsky, P., Fang, Y., Pittman, T., Roman, J., Wang, Y., Prueksaritanont, T., & Ionescu, R. (2011) · Molecular Immunology · doi:10.1016/j.molimm.2010.12.009 · Cited by 257
Neuberger, M. S., & Milstein, C. (1995) · Current Opinion in Immunology · doi:10.1016/0952-7915(95)80010-7 · Cited by 257
Collis, A. V. J., Brouwer, A. P., & Martin, A. C. R. (2003) · Journal of Molecular Biology · doi:10.1016/s0022-2836(02)01222-6 · Cited by 256
Mechanisms of action of CD20 antibodies.
Boross, P., & Leusen, J. H. W. (2012) · PubMed · Cited by 252
Electrostatic complementarity at protein/protein interfaces 1 1Edited by B. Honig
McCoy, A. J., Chandana Epa, V, & Colman, P. M. (1997) · Journal of Molecular Biology · doi:10.1006/jmbi.1997.0987 · Cited by 252
Docking, scoring, and affinity prediction in CAPRI
Lensink, M. F., & Wodak, S. J. (2013) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.24428 · Cited by 249
Wilson, N. S., Yang, B., Yang, A., Loeser, S., Marsters, S., Lawrence, D., Li, Y., Pitti, R., Totpal, K., Yee, S., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.11.012 · Cited by 248
Martin, A. C. R., & Thornton, J. M. (1996) · Journal of Molecular Biology · doi:10.1006/jmbi.1996.0617 · Cited by 246
Honegger, A., & Plückthun, A. (2001) · Journal of Molecular Biology · doi:10.1006/jmbi.2001.4662 · Cited by 246
Kaplon, H., & Reichert, J. M. (2018) · mAbs · doi:10.1080/19420862.2018.1415671 · Cited by 244
Contrasting IgG Structures Reveal Extreme Asymmetry and Flexibility
Saphire, E. O., Stanfield, R. L., Max Crispin, M. D., Parren, P. W. H. I., Rudd, P. M., Dwek, R. A., Burton, D. R., & Wilson, I. A. (2002) · Journal of Molecular Biology · doi:10.1016/s0022-2836(02)00244-9 · Cited by 243
Increasing the serum persistence of an IgG fragment by random mutagenesis
Ghetie, V., Popov, S., Borvak, J., Radu, C., Matesoi, D., Medesan, C., Ober, R. J., & Ward, E. S. (1997) · Nature Biotechnology · doi:10.1038/nbt0797-637 · Cited by 241
In Vitro Characterization of Five Humanized OKT3 Effector Function Variant Antibodies
Xu, D., Alegre, M.-L., Varga, S. S., Rothermel, A. L., Collins, A. M., Pulito, V. L., Hanna, L. S., Dolan, K. P., Parren, P. W. H. I., Bluestone, J. A., et al. (2000) · Cellular Immunology · doi:10.1006/cimm.2000.1617 · Cited by 238
Hinman, L. M., Hamann, P. R., Wallace, R., Menendez, A. T., Durr, F. E., & Upeslacis, J. (1993) · PubMed · Cited by 236
Zhu, K., Day, T., Warshaviak, D., Murrett, C., Friesner, R., & Pearlman, D. (2014) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.24551 · Cited by 236
An Unfolded CH1 Domain Controls the Assembly and Secretion of IgG Antibodies
Feige, M. J., Groscurth, S., Marcinowski, M., Shimizu, Y., Kessler, H., Hendershot, L. M., & Buchner, J. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.04.028 · Cited by 236
Tramontano, A., Chothia, C., & Lesk, A. M. (1990) · Journal of Molecular Biology · doi:10.1016/s0022-2836(05)80102-0 · Cited by 236
[28] Cleavage at aspartic acid
Inglis, A. S. (1983) · Methods in Enzymology · doi:10.1016/s0076-6879(83)91030-3 · Cited by 235
Impact of methionine oxidation on the binding of human IgG1 to FcRn and Fcγ receptors
Bertolotti-Ciarlet, A., Wang, W., Lownes, R., Pristatsky, P., Fang, Y., McKelvey, T., Li, Y., Li, Y., Drummond, J., Prueksaritanont, T., et al. (2009) · Molecular Immunology · doi:10.1016/j.molimm.2009.02.002 · Cited by 235
Nanobody stabilization of G protein-coupled receptor conformational states
Steyaert, J., & Kobilka, B. K. (2011) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2011.06.011 · Cited by 234
Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface
Lewis, S. M., Wu, X., Pustilnik, A., Sereno, A., Huang, F., Rick, H. L., Guntas, G., Leaver-Fay, A., Smith, E. M., Ho, C., et al. (2014) · Nature Biotechnology · doi:10.1038/nbt.2797 · Cited by 234
Antibody Elbow Angles are Influenced by their Light Chain Class
Stanfield, R. L., Zemla, A., Wilson, I. A., & Rupp, B. (2006) · Journal of Molecular Biology · doi:10.1016/j.jmb.2006.01.023 · Cited by 233
Vauquelin, G., & Charlton, S. J. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12106 · Cited by 231
Interaction with FcγRIIB Is Critical for the Agonistic Activity of Anti-CD40 Monoclonal Antibody
White, A. L., Chan, H. T. C., Roghanian, A., French, R. R., Mockridge, C. I., Tutt, A. L., Dixon, S. V., Ajona, D., Verbeek, J. S., Al-Shamkhani, A., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1101135 · Cited by 226
Structural classification of CDR‐H3 in antibodies
Shirai, H., Kidera, A., & Nakamura, H. (1996) · FEBS Letters · doi:10.1016/s0014-5793(96)01252-5 · Cited by 223
Mapping the site on human IgG for binding of the MHC class I-related receptor, FcRn
Kim, J.-K., Firan, M., Radu, C. G., Kim, C.-H., Ghetie, V., & Ward, E. S. (1999) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199909)29:09<2819::aid-immu2819>3.0.co;2-6 · Cited by 222
Laursen, N. S., Friesen, R. H. E., Zhu, X., Jongeneelen, M., Blokland, S., Vermond, J., van Eijgen, A., Tang, C., van Diepen, H., Obmolova, G., et al. (2018) · Science · doi:10.1126/science.aaq0620 · Cited by 220
de Jong, R. N., Beurskens, F. J., Verploegen, S., Strumane, K., van Kampen, M. D., Voorhorst, M., Horstman, W., Engelberts, P. J., Oostindie, S. C., Wang, G., et al. (2016) · PLOS Biology · doi:10.1371/journal.pbio.1002344 · Cited by 219
Kabat, E. A., & Wu, T. T. (1971) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1971.tb13550.x · Cited by 218
Bolt, S., Routledge, E., Lloyd, I., Chatenoud, L., Pope, H., Gorman, S. D., Clark, M., & Waldmann, H. (1993) · European Journal of Immunology · doi:10.1002/eji.1830230216 · Cited by 218
de Wildt, R. M. T., Hoet, R. M. A., van Venrooij, W. J., Tomlinson, I. M., & Winter, G. (1999) · Journal of Molecular Biology · doi:10.1006/jmbi.1998.2396 · Cited by 215
Camelid and shark single domain antibodies: Structural features and therapeutic potential
Könning, D., Zielonka, S., Grzeschik, J., Empting, M., Valldorf, B., Krah, S., Schröter, C., Sellmann, C., Hock, B., & Kolmar, H. (2017) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2016.10.019 · Cited by 214
Tiller, T., Schuster, I., Deppe, D., Siegers, K., Strohner, R., Herrmann, T., Berenguer, M., Poujol, D., Stehle, J., Stark, Y., et al. (2013) · mAbs · doi:10.4161/mabs.24218 · Cited by 205
Post-translational Modifications of Recombinant Proteins: Significance for Biopharmaceuticals
Jenkins, N., Murphy, L., & Tyther, R. (2008) · Molecular Biotechnology · doi:10.1007/s12033-008-9049-4 · Cited by 204
Methionine oxidation in human IgG2 Fc decreases binding affinities to protein A and FcRn
Pan, H., Chen, K., Chu, L., Kinderman, F., Apostol, I., & Huang, G. (2009) · Protein Science · doi:10.1002/pro.45 · Cited by 203
Cited by
Olsen, T. H., Boyles, F., & Deane, C. M. (2022) · Protein Science · doi:10.1002/pro.4205 · Cited by 319
ImmuneBuilder: Deep-Learning models for predicting the structures of immune proteins
Abanades, B., Wong, W. K., Boyles, F., Georges, G., Bujotzek, A., & Deane, C. M. (2023) · Communications Biology · doi:10.1038/s42003-023-04927-7 · Cited by 298
Avidity in antibody effector functions and biotherapeutic drug design
Oostindie, S. C., Lazar, G. A., Schuurman, J., & Parren, P. W. H. I. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00501-8 · Cited by 298
AFsample: improving multimer prediction with AlphaFold using massive sampling
Wallner, B. (2023) · Bioinformatics · doi:10.1093/bioinformatics/btad573 · Cited by 164
ABlooper: fast accurate antibody CDR loop structure prediction with accuracy estimation
Abanades, B., Georges, G., Bujotzek, A., & Deane, C. M. (2022) · Bioinformatics · doi:10.1093/bioinformatics/btac016 · Cited by 157
Metadata
- Authors
- Chiu, M. L., Goulet, D. R., Teplyakov, A., & Gilliland, G. L.
- Venue
- Antibodies
- Publisher
- MDPI AG
- Published
- 2019-12-03
- Volume
- 8
- Issue
- 4
- Pages
- 55
- ISSN
- 2073-4468 (ISSN-L)
- OpenAlex
- W2993866869
- Cited by
- 638
- References
- 560
- FWCI
- 28.20
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.